~ 6 Phase 2 completed
~ 2 Phase 3 OnGoing
~ 4396 Images analysed
~ 5 GCP Audits OK'ed
~ 6 Phase 2 completed ~ 2 Phase 3 OnGoing ~ 4396 Images analysed ~ 5 GCP Audits OK'ed
FibroNest Visualizes and Quantifies the histological phenotype of Fibrosis and its associated Activity Features
Morphometry
MACRO Steatosis (L/M)
Ballooning
Architecture
Nuclear Inflammation
Tissue Architecture
AUGMENTED PATHOLOGY
Localization
SeptAL Bridge Severity
TISSUE PANELS
FibroNest Continuous Scores can show effect of a compound “inside” categorical stages
Evaluation of the multivendor performance of a novel histology-based fibrosis phenotypic composite score and its correlation with NASH-CRN Fibrosis scores in patients with NASH Li Chen (1), Michael Lung (2), Cynthia Behling (3), Anthony Azzara (4), Diane Shevell (4), Arun J. Sanyal (5), Mathieu Petitjean (1) - (1) Pharmanest, Princeton, NJ, USA (2) Pacific Rim Pathology, San Diego, CA, USA (3) Department of Pediatrics University of California, San Diego, CA, USA (4) Bristol Myers Squibb, Princeton, NJ, USA (5) Virginia Commonwealth University, Richmond, VA, USA Presented at AASLD 2021, #1601 (Poster Here)
Fibrosis Phenotyping establishes clinical continuous scores to assess the severity and progression of fibrosis
Continuous staging of NASH Patients at low (F1) Fibrosis Severity: Evaluation of the performance of a novel histology-based fibrosis phenotypic composite score and predictive AI tools. Li Chen (1), Dmitry Fedorov (2), Mathieu Petitjean (1), Benjamin J. Bruno (3), Kilyoung Kim (3), Cynthia Behling (4), Anthony DelConte (5), Nachiappan Chidambaram (3) - (1) Pharmanest Inc, Princeton, New Jersey, USA (2) ViQi Inc, Santa Barbara, California, USA (3) Lipocine Inc. Salt Lake City, Utah, USA (4) Pacific Rim Pathology, San Diego, CA, USA (5) Saint Joseph’s University, Philadelphia, PA, USA - Presented at AASLD 2021, #1587 (Poster Here)
The FibroNest method contributes to the discovery of new Antifibrotic Compounds
FibroNest is validated on Adult and Pediatric NASH, +20 different animal models and on 3DNASH Spheroids
In-Vitro human 3D NASH model as a screening-based discovery approach for selecting and prioritizing drug candidates. Simon Strӧbel, Jana Rupp, Katia Fiaschetti, Agnieska Pajat, Katarzyna Sanchez (1), Mathieu M. Petitjean, Li Chen (2), Manuela Bieri, Armin Wolf, Sue Grepper Eva Thoma, Radina Kostadinova (1). (1) InSphero AG, Schlieren, Switzerland (2) PharmaNest, Princeton, NJ, USA- Presented at AASLD 2021, #1906 (Poster Here)